

Article

Enantiomerically Enriched 1,2-*P,N*-Bidentate Ferrocenyl Ligands for 1,3-Dipolar Cycloaddition and Transfer Hydrogenation Reactions

Irina A. Utepova ^{1,2}, Polina O. Serebrennikova ¹, Marina S. Streltsova ¹,
Alexandra A. Musikhina ¹, Tatiana G. Fedorchenko ², Oleg N. Chupakhin ^{1,2,*}
and Andrey P. Antonchick ^{3,4,5}

¹ Ural Federal University, 19 Mira Street, Ekaterinburg 620002, Russia; i.a.utepova@urfu.ru (I.A.U.); spo-1803@yandex.ru (P.O.S.); strelcova-marina@mail.ru (M.S.S.); alexa5330@yandex.ru (A.A.M.)

² Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, 22 S. Kovalevskaya Street, Ekaterinburg 620041, Russia; deryabina@ios.uran.ru

³ Chemische Biologie, Max-Planck-Institut für Molekulare Physiologie, Otto-Hahn Strasse 11, 44227 Dortmund, Germany; andrey.antonchick@mpi-dortmund.mpg.de

⁴ Fakultät Chemie und Chemische Biologie, Technische Universität Dortmund, Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany

⁵ Faculty of Science, Peoples' Friendship University of Russia, 6 Miklukho-Maklaya Street, Moscow 117198, Russia

* Correspondence: chupakhin@ios.uran.ru; Tel.: +7-343-374-1189

Received: 14 May 2018; Accepted: 25 May 2018; Published: 30 May 2018



Abstract: Novel complexes of 1,2-*P,N*-bidentate ferrocenyl ligands with AgOAc or with [RuCl₂(PPh₃)₃] as catalysts have been studied in asymmetric synthesis. The catalytic activity of these systems have been studied in [3+2]-cycloaddition of azomethine ylides with olefins and the asymmetric transfer hydrogenation of ketones.

Keywords: ferrocenyl ligands; catalysis; cycloaddition; hydrogen transfer

1. Introduction

Planar chiral 1,2-bidentate ferrocenyl ligands, as well as binaphthyls, bi(hetero)aryls, and spirobiindans, are widely spread in versatile reactions of asymmetric synthesis reactions [1]. They are connected with the ability, at low concentrations, of the catalyst to provide a high degree of enantioselectivity and high yield of target products. Such ligands are essential for the production of pharmaceuticals and natural products.

To date, a variety of complexes from the available chiral ligands, including ferrocenes, with transition metals have been developed for asymmetric cycloaddition reactions. For example, Cu^I or Ag^I/TF-Biphosphos (ee up to 99%, C. -J. Wang) [2–5], Cu^I/Fesulphos (ee up to 96%, J. C. Carretero) [6,7], Ag^I/xylyl-FAP (ee up to 97%, X. Zhang) [8], Cu^I/Ming-Phos (ee up to 95%, J. Zhang) [9], Ag^I/QUINAP (ee up to 96%, S. L. Schreiber) [10], Ag^I/FPOX (ee up to 98%, Y. -G. Zhou) [11–13] and Ag^I/BINAP (ee up to 99%, J. M. Sansano) [14–17]. Ferrocene-based catalysts were successfully applied in the asymmetric [3+2]-cycloaddition of azomethine ylides with olefins as well [18–27]. Moreover, the use of ferrocenyl chiral complexes in small amounts, such as Rh/JoSPOphos [28], Ru/Josiphos [29], and Re^V/(*R,S*)-Josiphos [30], in enantioselective hydrogenation of carbonyl compounds, is significant for chemistry.

In our previous work, an efficient and straightforward route for the synthesis of planar chiral (hetaryl)ferrocenes *P,N*-ligands **L1** (*er* > 99:1) and **L2** (*er* > 99:1) (Figure 1) has been demonstrated [31]. The obtained (hetaryl)ferrocenes revealed high catalytic activity in the Pd-catalyzed Tsuji–Trost allylic

substitution [31]. In the present paper, the catalytic activity of chiral complexes based on the ligands **L1** and **L2** in the [3+2]-cycloaddition of azomethine ylides with olefins and the asymmetric transfer hydrogenation of ketones is demonstrated.




Figure 1. Planar chiral ferrocenyl ligands.

2. Results and Discussion

Asymmetric [3+2]-cycloaddition [32] represents one of the most efficient, straightforward, and atom-economical methods for the construction of optically active pyrrolidine derivatives with multiple stereocenters. After pioneering studies of asymmetric pyrrolidines synthesis [8,33], many efforts were directed to the development of synthetic approaches to novel chiral catalysts. Chiral pyrrolidines are present in many biologically active [34–36] and natural [37] compounds, and were recently often applied as organocatalysts [38–44]. For instance compound **1** demonstrates an antiviral activity against hepatitis C (as an inhibitor of RNA polymerase) [45,46], and α -kainic acid (**2**) has a neuroexcitatory effect [47]. (–)-Dysibetaine (**3**) is a neuroexcitotoxin which may bind to the glutamate receptors presented in the CNS of mice [48]. Hydroxyprolines **4** and **5** play an important role in the catabolism of collagen, and in the stabilization of protocollagens and glycoproteins in living systems [49]. Derivatives of pyrrolopyrans **6** [23] are known to be the analogues of natural monoterpenoids of the class of cyclopentanopyranes (iridoids), performing protective functions in the organism. Lactam **7** is thrombin inhibitor (Figure 2) [50].





Figure 2. Bioactive and natural compounds based on the pyrrolidine scaffold.


Given the importance of the pyrrolidine scaffold, we studied asymmetric [3+2]-cycloaddition using the developed chiral ligands. Initially, the cycloaddition of methyl (*E*)-2-((4-bromobenzylidene)imino)acetate (**8a**) to *N*-methylmaleimide (**9a**) was selected as a model reaction for testing the activity of new ligands, such as (*S*_{FC})-[2-(2-quinolin-2-yl)-ferrocen-1-yl]-diphenylphosphine (**L1**) and (*R*_{FC})-1-(quinolin-2-yl)-2-(*α*-(*R*)-diphenylphosphinoethyl)ferrocene (**L2**). The reaction was carried out in the presence of substoichiometric amounts of triethylamine and tetrakis(acetonitrile)copper(I) tetrafluoroborate (5 mol %) at room temperature. Product **10a** was obtained in 65% yield and *er* = 50:50 in absence of chiral ligand (Table 1, entry 1). Applying complex **L1** with tetrakis(acetonitrile)copper(I) tetrafluoroborate, product **10a** was obtained with an *er* = 76:24 and 45% yield (Table 1, entry 2). Afterwards, we tried to increase the yield and the selectivity of the reaction by employing various Lewis acids, such as AgF and AgOAc with **L1** (Table 1, entries 3 and 4) [2–4,15,16,51,52]. The reaction with **L1**/AgF resulted in 58% yield of product **10a** and *er* = 50:50. Using AgOAc with ligand (**L1**), the target product was formed with *er* = 85:15 and 50% yield. Complex **L1** with AgOAc was prepared in situ by stirring for 15 min at room temperature in dichloromethane. There was a change in the color of the reaction mixture from orange to dark red after the formation of the complex. The structure of complex **L1**/AgOAc was confirmed by nuclear magnetic resonance (NMR) spectroscopy, high-resolution mass spectrometry (HRMS), and elemental analysis (see Supplementary Materials page S2, S19, figures S2, S4, S20, S22). The signals of the protons of the ferrocene and heterocyclic moieties of the complex **L1**/AgOAc (3.9–5.4 and 7.4–7.9 ppm) are downfield shifted by 0.1–0.3 ppm and 0.1–0.2 ppm compared to those of the initial **L1** ligand (3.8–5.1 and 7.2–8.0 ppm). In the ³¹P spectra of the complex, a downfield shift by 5.9 ppm relative to the free ligand was also observed.

Table 1. Asymmetric [3+2]-cycloaddition of methyl (*E*)-2-((4-bromobenzylidene)imino)acetate **8a** and *N*-methylmaleimide **9a**.



Entry	Ligand	[M]/Base	Yield (%) 10a	<i>er</i> (%) 10a
1	-	[Cu(CH ₃ CN) ₄][BF ₄]/Et ₃ N	65	50:50
2	L1	[Cu(CH ₃ CN) ₄][BF ₄]/Et ₃ N	45	76:24
3	L1	AgF/Et ₃ N	50	50:50
4	L1	AgOAc/Et ₃ N	50	85:15


Based on the above results, we concluded that the optimal conditions for this transformation are as follows: dichloromethane, 5 mol % AgOAc, 6 mol % ligand, and room temperature. In order to investigate the effect of the substituent on the yield and selectivity of the products, imino esters **8** with donor and acceptor substituents in the benzene ring were synthesized [23,53]. The cycloaddition of methyl (*E*)-2-((4-bromobenzylidene)imino)acetate (**8a**) and methyl (*E*)-2-((4-chlorobenzylidene)imino)acetate (**8b**) with *N*-methylmaleimide (**9a**) led to the formation of products **10a** and **10b** in 50% and 69% yields, respectively (Scheme 1). A similar reaction of **8a** and **8b** with *N*-phenylmaleimide (**9b**) proceeded with the formation of products **10d** and **10e** in 64% and 34% yields and 98:2 and 93:7 *er*, respectively (Scheme 1). The attempt to employ methyl (*E*)-2-((4-methoxybenzylidene)imino)acetate failed. Product **10c** was obtained in 45% yield and *er* = 63:37 using *N*-methylmaleimide as a dipolarophile, and its structural analogue **10f** was obtained in 60% yield and *er* = 70:30 using *N*-phenylmaleimide.



Scheme 1. Reaction of [3+2]-cycloaddition of methyl (E)-2-((4-substituted-benzylidene)imino)acetate (**8**) and *N*-alkylmaleimide (**9**) catalyzed by the complex **L1**/AgOAc: ^a The enantiomeric ratio was determined by high-performance liquid chromatography (HPLC) on a Chiralpak AD. ^b The enantiomeric ratio was determined by HPLC on a Chiralcel OD-H. ^c The enantiomeric ratio was determined by supercritical fluid chromatography (SFC) on a Chiralcel OD-H. ^d Use of the **L2**/AgOAc complex.

Notably, using (R_{Fe})-1-(quinolin-2-yl)-2-(α -(*R*)-diphenylphosphinoethyl)ferrocene **L2**, the product **10d** was obtained in 55% yield as a racemate (*er* = 50:50) using the optimized reaction conditions (Scheme 1).

A plausible mechanism is shown in Scheme 2. In the first step of the reaction, silver(I) is simultaneously coordinated by the bidentate chiral ligand **L1** and the substrate **8** in a tetrahedral arrangement to form the catalytic complex **A**. Next step of deprotonation of complex **A** by triethylamine leads to the formation of the azomethine ylide, the active substrate for the cycloaddition. This active substrate then undergoes a cycloaddition with dienophile **9** to furnish the product **10a** (Scheme 2). The dienophile attacks from the less-hindered side (above the plane), to avoid unfavorable steric interactions with the bulky diphenylphosphine group of the ligand [20].



Scheme 2. A plausible mechanism of [3+2] cycloaddition of imino ester **8a** and dienophile **9a**.

The structures of the cycloaddition products **10a–f** have been confirmed by NMR spectroscopy, and the data corresponding well with the literature [53,54]. In addition, we carried out nuclear Overhauser effect spectroscopy (NOESY) experiments for compound **10a**, to gain structural and stereochemical information. The NOESY experiment showed a NOE effect of the H-3 to H-3a, and H-1 to H-6a, enabling the determination of the stereochemistry of this compound as *endo*-product (Figure 3). Absolute configuration was determined by comparison with the literature data [54]. The enantiomeric ratio of the compounds was determined by high-performance liquid chromatography (HPLC) and supercritical fluid chromatography (SFC) analysis.




Figure 3. NOESY (H↔H) correlations of compound **10a**.

The asymmetric hydrogenation of double bonds is known to be of great importance in the synthesis of biologically active compounds and their precursors. For example, (*S*)-Duloxetine (**11**) is an antidepressant drug targeting the presynaptic cell and (*R*)-Fluoxetine (**12**) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class (Figure 4) [55–57]. In particular, ferrocenyl chiral complexes [29,30,58,59] are utilized for the carbonyl group reduction.





Figure 4. Biologically active compounds obtained by the reaction of asymmetric reduction.

Next, we tried to examine the catalytic activity of planar chiral ferrocenyl ligands **L1** and **L2** applying the Ru-catalyzed transfer hydrogenation of ketones with acetophenone **13** as a model substrate (Scheme 3, Table 2).



Scheme 3. Asymmetric transfer hydrogenation of acetophenone **13** in the presence of the complex **L1**/RuCl₂(PPh₃)₃ or **L2**/RuCl₂(PPh₃)₃.

According to the standard procedure [29], the reaction was carried out in the presence of catalytic amounts of base and the active complex **L1**/RuCl₂(PPh₃)₃ in degassed *i*PrOH. The reaction of **L1** with [RuCl₂(PPh₃)₃] in toluene at room temperature for 10 min gave the desired red complex. The structure of complex **L1**/RuCl₂(PPh₃)₃ has been confirmed by NMR spectroscopy HRMS and elemental analysis (see Supplementary Materials page S2, S22, figures S3, S5, S21, S23). The ¹H-NMR spectra point out that the proton signals of the ferrocene and heterocyclic moieties of the complex **L1**/RuCl₂(PPh₃)₃

(3.9–5.4 and 7.4–7.9 ppm) in comparison to the initial ligand **L1** (3.8–5.1 and 7.2–8.0 ppm) are downfield shifted by 0.1–0.3 ppm and 0.1–0.2 ppm, respectively. It should be noted that in the ^{31}P spectra of the complex, the signal is downfield shifted by 5.6 ppm relative to the initial ligand.

Asymmetric transfer hydrogenation of acetophenone **13** to (*R*)-1-phenylethanol **14** was carried out in the presence of 0.5 mol % of complex **L1**/ $\text{RuCl}_2(\text{PPh}_3)_3$ and 2 mol % *t*-BuOK. The reaction mixture was stirred under argon atmosphere for 20 h at room temperature. (*R*)-1-phenylethanol **14** was isolated by column chromatography on SiO_2 in 20% yield and with the selectivity of more than 99% (Table 2, entry 2). The asymmetric transfer hydrogenation conditions were optimized with respect to the type and amount of base and the reaction temperature (Table 2).

The application of 4-dimethylaminopyridine (DMAP) and NaH as bases provided low yields of product **14** (Table 2, entries 3 and 4). Furthermore, **14** was obtained in 2% yield after 72 h in the presence of 20 mol % using triethylamine as base (Table 2, entry 5). Next, we tried to increase the yield by heating to 80 °C (Table 2, entry 6). At last, (*R*)-1-phenylethanol **14** in 98% yield was achieved by carrying out the reaction at 80 °C in the presence of 20 mol % *t*-BuOK (Table 2, entry 7). Reducing the loading of *t*-BuOK to 10 and 2 mol % resulted in a slight decrease in the product yield (Table 2, entries 8 and 9). The selectivity of the process in all above cases with **L1**/ $\text{RuCl}_2(\text{PPh}_3)_3$ was more than 99%.


Table 2. Transfer hydrogenation of acetophenone **15** under different reaction conditions.

Entry	Ligand	<i>T</i> (°C)	Base (mol %)	Time (h)	Yield (%) 14	<i>er</i> (%) ¹ 14
1	-	RT	<i>t</i> -BuOK (2)	48	30 ²	1:1
2	L1	RT	<i>t</i> -BuOK (2)	48	20 ²	>99:1
3	L1	RT	DMAP (2)	48	-	-
4	L1	RT	NaH (2)	48	11 ³	>99:1
5	L1	RT	Et_3N (20)	72	2 ³	>99:1
6	L1	80	Et_3N (20)	20	40 ³	>99:1
7	L1	80	<i>t</i> -BuOK (20)	20	98 ³	>99:1
8	L1	80	<i>t</i> -BuOK (10)	20	97 ³	>99:1
9	L1	80	<i>t</i> -BuOK (2)	20	96 ³	>99:1
10	L2	80	<i>t</i> -BuOK (20)	20	53 ³	>99:1

¹ The enantiomeric ratio was determined by SFC on a Lux Amylose-2. ² The product was isolated by column chromatography on SiO_2 . ³ The yield was determined by NMR spectroscopy.

In the reaction with **L2**/ $\text{RuCl}_2(\text{PPh}_3)_3$ complex, the selectivity of (*R*)-1-phenylethanol (**14**) was also more than 99% with a yield of 53% (Table 2, entry 10).

Based on the above results, we conclude that the optimal conditions for this transformation are as follows: 20 mol % *t*-BuOK, 0.5 mol % ligand, 0.5 mol % $\text{RuCl}_2(\text{PPh}_3)_3$ and 80 °C. In order to investigate the effect of the substituent on the yield and selectivity of the products, other ketones were used (Scheme 4). The asymmetric transfer hydrogenation of 2-butanone **13b** led to the formation of products **14b** in 50% yields. Next, we investigated the ability of using of asymmetric transfer hydrogenation for π -excess and π -deficient carbonyl compounds such as 2-acetylthiophene **13c** and 2-acetylpyridine **13d** (Scheme 4). (*R*)-1-(Thiophen-2-yl)ethan-1-ol **14c** was isolated in trace amounts. This is interpreted by the instability of thiophene derivatives. As opposed to 2-acetylthiophene, the asymmetric transfer hydrogenation of π -deficient 2-acetylpyridine **13d** led to the formation of products **14d** in high yield and selectivity (Scheme 4).



Scheme 4. Asymmetric transfer hydrogenation of carbonyl compounds **13** in the presence of the complex **L1**/ $\text{RuCl}_2(\text{PPh}_3)_3$.

3. Materials and Methods

3.1. General Information

All reactions were carried out under argon using standard Schlenk Techniques (Hofmann Glastechnik GmbH, Staudt, Germany). The ^1H -NMR (400 MHz), ^{13}C -NMR (100 MHz), ^{31}P -NMR (162 MHz) spectra were recorded on a NMR spectrometer (400 MHz). Chemical shifts are given in δ values (ppm) using tetramethylsilane (TMS) as internal standard and CDCl_3 as solvent. Electrospray mass spectra were recorded in positive mode with maXis impact high resolution Q-TOF mass spectrometer (Bruker Daltonics, Bremen, Germany) in 50–2500 Da mass range by direct infusion of sample solutions in methanol using kdScientific (KD Scientific Inc., Holliston, MA, USA) syringe pump at 120 $\mu\text{L}/\text{h}$ flow rate. Modified instrument settings of a pre-installed method Direct_Infusion_100–1000 were used. Mass calibration was performed using ES-TOF G1969-85000 tuning mix (Agilent Technologies) by HPC method (High Precision Calibration standard procedure by Bruker). All data were collected and analyzed with Compass for oToF series 1.7/DataAnalysis 4.2 software package (Bruker, Germany). Analytical HPLC (Knauer, Berlin, Germany) and SFC (Waters Corporation, Milford, MA, USA) were performed using a chiral column. The angle of rotation was measured on a polarimeter Perkin-Elmer 343+ (PerkinElmer Instruments, Llantrisant, Wales, UK). The elemental analysis was carried out on a CHNS/O analyzer Perkin-Elmer (PerkinElmer Instruments, Norwalk, CT, USA). The course of the reactions was monitored by thin layer chromatography (TLC) on silica gel plates (Macherey-Nagel GmbH & Co, Düren, Germany). The column chromatography was performed on silica gel (silica gel 60, 0.035–0.070 mm, 220–440 mesh).

Glycine methyl ester hydrochloride, *N*-methylmaleimide, *N*-phenylmaleimide, benzaldehydes, acetophenone, $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$, AgF, AgOAc, and $[\text{RuCl}_2(\text{PPh}_3)_3]$ were purchased from Aldrich (Merck KGaA, Darmstadt, Germany). (*S*_{FC})-[2-(2-quinolin-2-yl)-ferrocen-1-yl]-diphenylphosphine (**L1**), (*R*_{FC})-1-(quinolin-2-yl)-2-(α -(*R*)-diphenyl-phosphinoethyl)ferrocene (**L2**) [31] and imine **8** [23] were prepared according to the published procedures.

3.2. General Procedure for the Synthesis of Products 10

Ligand **L1** (6 mol %) and AgOAc (5 mol %) were dissolved in dichloromethane (1.0 mL) and the solution was stirred for 15 min at room temperature. Then, dipolarophile **9** (1.2 mmol), imine **8** (1 mmol) and Et_3N (20 mol %) were added to the mixture and stirred at room temperature for 24 h. After evaporation under reduced pressure, the residue was purified through column chromatography on silica gel (hexane/ethyl acetate = 9/1) to give the pure products. The structures of products were known [53,54] and confirmed by NMR. The enantiomeric excesses of the products were determined by HPLC and SFC on chiral stationary phase.

Methyl (1R,3S,3aR,6aS)-3-(4-bromophenyl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (10a) [54]. Obtained from imine **8a** and *N*-methylmaleimide **9a**, 0.183 g, 50%, white solid; $[\alpha]_D^{20} = +2.7$ (c 0.16, CDCl₃); HPLC: Chiralpak AD, $\lambda = 220$ nm, hexane/*i*PrOH/MeOH, 50:20:5, 0.6 mL/min, retention time (t_R): 20.5 min and 27.8 min.

Methyl (1R,3S,3aR,6aS)-3-(4-chlorophenyl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (10b) [54]. Obtained from imine **8b** and *N*-methylmaleimide **9a**, 0.222 g, 69%, gray solid; $[\alpha]_D^{20} = +2.4$ (c 0.15, CDCl₃); HPLC: Chiralpak AD, $\lambda = 220$ nm, hexane/*i*PrOH/MeOH, 50:25:5, 1 mL/min, t_R : 10.45 min and 14.22 min.

Methyl(1R,3S,3aR,6aS)-3-(4-methoxyphenyl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (10c) [54]. Obtained from imine **8b** and *N*-methylmaleimide **9a**, 0.143 g, 45%, dark beige solid; $[\alpha]_D^{20} = -0.7$ (c 0.12, CDCl₃); HPLC: Chiralpak AD, $\lambda = 220$ nm, hexane/*i*PrOH/MeOH, 50:25:5, 1 mL/min, t_R : 13.87 min and 17.42 min.

Methyl (1R,3S,3aR,6aS)-3-(4-bromophenyl)-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (10d) [53]. Obtained from imine **8a** and *N*-phenylmaleimide **9b**, 0.274 g, 64%, light gray solid; $[\alpha]_D^{20} = +61.3$ (c 0.15, CDCl₃); SFC: Chiralcel OD-H, $\lambda = 220$ nm, CO₂/MeOH, 75:25, 0.8 mL/min, 140 bar, t_R : 15.74 min and 24.67 min).

Methyl (1R,3S,3aR,6aS)-3-(4-chlorophenyl)-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (10e) [53]. Obtained from imine **8b** and *N*-phenylmaleimide **9b**, 0.130 g, 34%, dark gray solid; $[\alpha]_D^{20} = +3.4$ (c 0.1, CDCl₃); HPLC: Chiralcel OD-H, $\lambda = 220$ nm, hexane/*i*PrOH/MeOH, 50:20:5, 1 mL/min, t_R : 21.80 min and 28.18 min).

Methyl(1R,3S,3aR,6aS)-3-(4-methoxyphenyl)-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (10f) [53]. Obtained from imine **8c** and *N*-phenylmaleimide **9b**, 0.228 g, 60%, beige solid; $[\alpha]_D^{20} = -0.2$ (c 0.14, CDCl₃); SFC: Chiralcel OD-H, $\lambda = 220$ nm, CO₂/MeOH, 75:25, 0.8 mL/min, 140 bar, t_R : 15.57 min and 22.28 min.

3.3. General Procedure for the Synthesis of Products 14

A solution of ketone (1 mmol) and a base (20 mol %) was added to a solution of complex **L1**/RuCl₂(PPh₃)₃ (0.5 mol %) in degassed *i*PrOH (30 mL). The reaction mixture was stirred at 80 °C for 20 h, and the progress of the reaction was monitored by TLC. After evaporation under reduced pressure, the residue was purified through column chromatography on silica gel to yield pure product. The structures of products were known and were confirmed by NMR spectroscopy.

(R)-1-Phenylethanol (14a) [30]. Obtained from acetophenone **13a**, 0.120 mg, 98%, yellow oil; $[\alpha]_D^{20} = +1.3$ (c 0.06, CDCl₃); SFC: Lux Amylose-2, $\lambda = 210$ nm, CO₂/MeOH, 98:2, 1 mL/min, 140 bar, t_R : 6.1 min.

(R)-2-Butanol (14b) [60]. Obtained from 2-butanone **13b**, 0.037 g, 50%; SFC: Lux Amylose-2, $\lambda = 275$ nm, CO₂/MeOH, 95:5, 0.8 mL/min, 140 bar, t_R : 5.1 min.

(R)-1-(Pyridin-2-yl)ethanol (14d) [61]. Obtained from 2-acetylpyridine **13d**, 0.102 g, 83%; SFC: Chiralcel OD-H, $\lambda = 266$ nm, CO₂/MeOH, 90:10, 1 mL/min, 140 bar, t_R : 2.4 min.

4. Conclusions

New Ag- and Ru-catalysts based on the planar chiral ferrocene *P,N*-ligands **L1** and **L2** have been obtained. The scope of activity of the complexes was demonstrated in two types of asymmetric reactions: [3+2]-cycloaddition of azomethine ylides with olefins and asymmetric transfer hydrogenation of carbonyl compounds. The catalytic activity of the ligands **L1** and **L2** has been shown to be comparable with the ones of previously described ligands in the presented transformations. Thus, the obtained complexes revealed high reactivity and good enantioselectivity and enabled to access to optically active pyrrolidine derivatives and products of reduction of multiple bonds under

mild conditions. As the final step, we succeeded to apply the approach to the synthesis of potential biologically active compounds.

Supplementary Materials: The following are available online. The Supporting Materials contains copies of all ^1H -, ^{13}C - and ^{31}P -NMR spectra, HPLC, SFC, HRMS and elemental analysis data.

Author Contributions: All authors contributed to and approved the final manuscript.

Funding: This research was funded by Russian Science Foundation grant number 14-13-01177 and the Ministry of Education and Science of the Russian Federation grant number 4.6351.2017/8.9.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Dai, L.-X.; Hou, X.-L. (Eds.) *Chiral Ferrocenes in Asymmetric Catalysis*; Wiley-VCH: Weinheim, Germany, 2010; ISBN 9783527628841.
2. Xue, Z.-Y.; Liu, T.-L.; Lu, Z.; Huang, H.; Tao, H.-Y.; Wang, C.-J. exo-Selective asymmetric 1,3-dipolar cycloaddition of azomethine ylides with alkylidene malonates catalyzed by AgOAc/TF-Biphosphos. *Chem. Commun.* **2010**, *46*, 1727–1729. [[CrossRef](#)] [[PubMed](#)]
3. Wang, C.-J.; Xue, Z.-Y.; Liang, G.; Lu, Z. Highly enantioselective 1,3-dipolar cycloaddition of azomethine ylides catalyzed by AgOAc/TF-Biphosphos. *Chem. Commun.* **2009**, *45*, 2905–2907. [[CrossRef](#)] [[PubMed](#)]
4. Liang, G.; Tong, M.-C.; Wang, C.-J. Silver acetate/TF-Biphosphos-catalyzed endo-selective enantioselective 1,3-dipolar cycloaddition of azomethine ylides with vinyl phenyl sulfone. *Adv. Synth. Catal.* **2009**, *351*, 3101–3106. [[CrossRef](#)]
5. Wang, C.-J.; Liang, G.; Xue, Z.-Y.; Gao, F.J. Highly enantioselective 1,3-dipolar cycloaddition of azomethine ylides catalyzed by copper(I)/TF-Biphosphos complexes. *J. Am. Chem. Soc.* **2008**, *130*, 17250–17251. [[CrossRef](#)] [[PubMed](#)]
6. Hernández-Torbio, J.; Arrayás, R.G.; Martín-Mature, B.; Carretero, J.C. Catalytic asymmetric 1,3-dipolar cycloaddition of azomethine ylides with α,β -unsaturated ketones. *Org. Lett.* **2009**, *11*, 393–396. [[CrossRef](#)] [[PubMed](#)]
7. López-Pérez, A.; Adrio, J.; Carretero, J.C. The phenylsulfonyl group as a temporal regiochemical controller in the catalytic asymmetric 1,3-dipolar cycloaddition of azomethine ylides. *Angew. Chem. Int. Ed.* **2009**, *48*, 340–343. [[CrossRef](#)] [[PubMed](#)]
8. Longmire, J.M.; Wang, B.; Zhang, X. Highly enantioselective Ag(I)-catalyzed [3+2] cycloaddition of azomethine ylides. *J. Am. Chem. Soc.* **2002**, *124*, 13400–13401. [[CrossRef](#)] [[PubMed](#)]
9. Xu, B.; Zhang, Z.-M.; Xu, S.; Liu, B.; Xiao, Y.; Zhang, J. Copper(I)/Ming-Phos-catalyzed asymmetric intermolecular [3+2] cycloaddition of azomethine ylides with α -trifluoromethyl α,β -unsaturated esters. *ACS Catal.* **2017**, *7*, 210–214. [[CrossRef](#)]
10. Chen, C.; Li, X.; Schreiber, S.L. Catalytic asymmetric [3+2] cycloaddition of azomethine ylides. Development of a versatile stepwise, three-component reaction for diversity-oriented synthesis. *J. Am. Chem. Soc.* **2003**, *125*, 10174–10175. [[CrossRef](#)] [[PubMed](#)]
11. Zeng, W.; Zhou, Y.-G. Bifunctional AgOAc-catalyzed asymmetric [3+2] cycloaddition of azomethine ylides. *Org. Lett.* **2005**, *7*, 5055–5058. [[CrossRef](#)] [[PubMed](#)]
12. Gao, W.; Zhang, X.; Raghunath, M. Cu(I)-Catalyzed highly exo-selective and enantioselective [3+2] cycloaddition of azomethine ylides with acrylates. *Org. Lett.* **2005**, *7*, 4241–4244. [[CrossRef](#)] [[PubMed](#)]
13. Yan, X.-X.; Peng, Q.; Zhang, Y.; Zhang, K.; Hong, W.; Hou, X.-L.; Wu, Y.-D. A highly enantio- and diastereoselective Cu-catalyzed 1,3-dipolar cycloaddition of azomethine ylides with nitroalkenes. *Angew. Chem. Int. Ed.* **2006**, *45*, 1979–1983. [[CrossRef](#)] [[PubMed](#)]
14. Martín-Rodríguez, M.; Nájera, C.; Sansano, J.M.; Costa, P.R.R.; de Lima, E.C.; Dias, A.G. BINAP–AgSbF₆ vs. BINAP–AgClO₄ complexes as catalysts for the enantioselective 1,3-dipolar cycloaddition of azomethine ylides and alkenes. *Synlett* **2010**, 962–966. [[CrossRef](#)]
15. Nájera, C.; de Gracia Retamosa, M.; Sansano, J.M.; de Cózar, A.; Cossío, F.P. Enantioselective synthesis of polysubstituted prolines by Binap-silver-catalyzed 1,3-dipolar cycloadditions. *Tetrahedron: Asymmetry* **2008**, *19*, 2913–2923. [[CrossRef](#)]

16. Nájera, C.; de Gracia Retamosa, M.; Sansano, J.M. Recoverable (R)- and (S)-Binap-Ag(I) complexes for the enantioselective 1,3-dipolar cycloaddition reaction of azomethine ylides. *Org. Lett.* **2007**, *9*, 4025–4028. [[CrossRef](#)] [[PubMed](#)]
17. Mancebo-Aracil, J.; Martín-Rodríguez, M.; Nájera, C.; Sansano, J.M.; Costa, P.R.R.; de Lima, E.C.; Dias, A.G. Binap-silver salts as chiral catalysts for the enantioselective 1,3-dipolar cycloaddition of azomethine ylides and alkenes. *Tetrahedron Asymmetry* **2012**, *23*, 1596–1606. [[CrossRef](#)]
18. Pandey, G.; Banerjee, P.; Gadre, S.R. Construction of enantiopure pyrrolidine ring system via asymmetric [3+2]-cycloaddition of azomethine ylides. *Chem. Rev.* **2006**, *106*, 4484–4517. [[CrossRef](#)] [[PubMed](#)]
19. Stanley, L.M.; Sibi, M.P. Enantioselective copper-catalyzed 1,3-dipolar cycloadditions. *Chem. Rev.* **2008**, *108*, 2887–2902. [[CrossRef](#)] [[PubMed](#)]
20. Narayan, R.; Potowski, M.; Jia, Z.-J.; Antonchick, A.P.; Waldmann, H. Catalytic enantioselective 1,3-dipolar cycloadditions of azomethine ylides for biology-oriented synthesis. *Acc. Chem. Res.* **2014**, *47*, 1296–1310. [[CrossRef](#)] [[PubMed](#)]
21. Watanabe, S.; Tada, A.; Tokoro, Y.; Fukuzawa, S.-I. Bifunctional AgOAc/ThioClickFerrophos complex-catalyzed asymmetric 1,3-dipolar cycloaddition of azomethine ylides with aryl- and alkylidene malonates. *Tetrahedron Lett.* **2014**, *55*, 1306–1309. [[CrossRef](#)]
22. Wang, H.; Deng, Q.; Zhou, Z.; Hu, S.; Liu, Z.; Zhou, L.-Y. Ag₂CO₃/CA-AA-AmidPhos multifunctional catalysis in the enantioselective 1,3-dipolar cycloaddition of azomethine ylides. *Org. Lett.* **2016**, *18*, 404–407. [[CrossRef](#)] [[PubMed](#)]
23. Takayama, H.; Jia, Z.-J.; Kremer, L.; Bauer, J.O.; Strohmman, C.; Ziegler, S.; Antonchick, A.P.; Waldmann, H. Discovery of inhibitors of the Wnt and Hedgehog signaling pathways through the catalytic enantioselective synthesis of an iridoid-inspired compound collection. *Angew. Chem. Int. Ed.* **2013**, *52*, 12404–12408. [[CrossRef](#)] [[PubMed](#)]
24. Potowski, M.; Merten, C.; Antonchick, A.P.; Waldmann, H. Catalytic aerobic oxidation and tandem enantioselective cycloaddition in cascade multicomponent synthesis. *Chem. Eur. J.* **2015**, *21*, 4913–4917. [[CrossRef](#)] [[PubMed](#)]
25. Potowski, M.; Golz, C.; Strohmman, C.; Antonchick, A.P.; Waldmann, H. Biology-oriented synthesis of benzopyrano[3,4-c]pyrrolidines. *Bioorg. Med. Chem.* **2015**, *23*, 2895–2903. [[CrossRef](#)] [[PubMed](#)]
26. Chang, G.-H.; Wang, C.-Y.; Reddy, G.M.; Tsai, Y.-L.; Lin, W.J. Enantioselective synthesis of polysubstituted benzopyrano[3,4-c]pyrrolidine frameworks via [3+2] cycloaddition of azomethine ylides and coumarin derivatives. *Org. Chem.* **2016**, *81*, 10071–10080. [[CrossRef](#)] [[PubMed](#)]
27. Bai, X.-F.; Zhang, J.; Xia, C.-G.; Xu, J.-X.; Xu, L.-W. N-tert-Butanesulfinyl imine and aromatic tertiary amide derived non-biaryl atropisomers as chiral ligands for silver-catalyzed endoselective [3+2] cycloaddition of azomethine ylides with maleimides. *Tetrahedron* **2016**, *72*, 2690–2699. [[CrossRef](#)]
28. Landert, H.; Spindler, F.; Wyss, A.; Blaser, H.-U.; Pugin, B.; Ribourduille, Y.; Gschwend, B.; Ramalingam, B.; Pfaltz, A. Chiral mixed secondary phosphine-oxide-phosphines: High-performing and easily accessible ligands for asymmetric hydrogenation. *Angew. Chem. Int. Ed.* **2010**, *49*, 6873–6876. [[CrossRef](#)] [[PubMed](#)]
29. Baratta, W.; Chelucci, G.; Magnolia, S.; Siega, K.; Rigo, P. Highly productive CNN pincer ruthenium catalysts for the asymmetric reduction of alkyl aryl ketones. *Chem. Eur. J.* **2009**, *15*, 726–732. [[CrossRef](#)] [[PubMed](#)]
30. Mejía, E.; Aardoom, R.; Togni, A. Asymmetric transfer hydrogenation of ketones catalyzed by rhenium complexes with chiral ferrocenylphosphane ligands. *Eur. J. Inorg. Chem.* **2012**, 5021–5032. [[CrossRef](#)]
31. Utepova, I.A.; Chupakhin, O.N.; Serebrennikova, P.O.; Musikhina, A.A.; Charushin, V.N. Two approaches in the synthesis of planar chiral azinylferrocenes. *J. Org. Chem.* **2014**, *79*, 8659–8667. [[CrossRef](#)] [[PubMed](#)]
32. Ali Döndas, H.; de Gracia Retamosa, M.; Sansano, J.M. Current trends towards the synthesis of bioactive heterocycles and natural products using 1,3-dipolar cycloadditions (1,3-DC) with azomethine ylides. *Synthesis* **2017**, *49*, 2819–2851. [[CrossRef](#)]
33. Gothelf, A.S.; Gothelf, K.V.; Hazell, R.G.; Jørgensen, K.A. Catalytic asymmetric 1,3-dipolar cycloaddition reactions of azomethine ylides—A simple approach to optically active highly functionalized proline derivatives. *Angew. Chem. Int. Ed.* **2002**, *41*, 4236–4238. [[CrossRef](#)]
34. Galliford, C.V.; Scheidt, K.A. Pyrrolidinyl-spirooxindole natural products as inspirations for the development of potential therapeutic agents. *Angew. Chem. Int. Ed.* **2007**, *46*, 8748–8758. [[CrossRef](#)] [[PubMed](#)]
35. Nájera, C.; Sansano, J.M. 1,3-Dipolar cycloadditions: Applications to the synthesis of antiviral agents. *Org. Biomol. Chem.* **2009**, *7*, 4567–4581. [[CrossRef](#)] [[PubMed](#)]

36. Arai, T.; Tokumitsu, C.; Miyazaki, T.; Kuwano, S.; Awata, A. Catalytic asymmetric [3+2]-cycloaddition for stereodivergent synthesis of chiral indolyl-pyrrolidines. *Org. Biomol. Chem.* **2016**, *14*, 1831–1839. [[CrossRef](#)] [[PubMed](#)]
37. O'Hagan, D. Pyrrole, pyrrolidine, pyridine, piperidine and tropane alkaloids. *Nat. Prod. Rep.* **2000**, *17*, 435–446. [[CrossRef](#)] [[PubMed](#)]
38. Gruttadauria, M.; Giacalone, F.; Noto, R. Supported proline and proline-derivatives as recyclable organocatalysts. *Chem. Soc. Rev.* **2008**, *37*, 1666–1688. [[CrossRef](#)] [[PubMed](#)]
39. Guillena, G.; Nájera, C.; Ramón, D.J. Enantioselective direct aldol reaction: The blossoming of modern organocatalysis. *Tetrahedron Asymmetry* **2007**, *18*, 2249–2293. [[CrossRef](#)]
40. Pellisser, H. Asymmetric organocatalysis. *Tetrahedron* **2007**, *63*, 9267–9331. [[CrossRef](#)]
41. *Asymmetric Organocatalysis: From Biomimetic Concepts to Applications in Asymmetric Synthesis*; Wiley-VCH: Weinheim, Germany, 2005; ISBN 978-3-527-30517-9.
42. Mukherjee, S.; Yang, J.W.; Hoffmann, S.; List, B. Asymmetric enamine catalysis. *Chem. Rev.* **2007**, *107*, 5471–5569. [[CrossRef](#)] [[PubMed](#)]
43. Dalko, P.I. (Ed.) *Enantioselective Organocatalysis: Reactions and Experimental Procedures*; Wiley-VCH: Weinheim, Germany, 2007; ISBN 9783527610945.
44. Erkkilä, A.; Majander, I.; Pihko, P.M. Iminium catalysis. *Chem. Rev.* **2007**, *107*, 5416–5470. [[CrossRef](#)] [[PubMed](#)]
45. Burton, G.; Ku, T.W.; Carr, T.J.; Kiesow, T.; Sarisky, R.T.; Lin-Goerke, J.; Baker, A.; Earnshaw, D.L.; Hofmann, G.A.; Keenan, R.M.; et al. Identification of small molecule inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1553–1556. [[CrossRef](#)] [[PubMed](#)]
46. Nájera, C.; de Gracia Retamosa, M.; Sansano, J.M.; de Cózar, A.; Cossío, F.P. Diastereoselective 1,3-dipolar cycloaddition reactions between azomethine ylides and chiral acrylates derived from methyl (S)- and (R)-lactate—Synthesis of hepatitis C virus RNA-dependent RNA polymerase inhibitors. *Eur. J. Org. Chem.* **2007**, 5038–5049. [[CrossRef](#)]
47. Farwick, A.; Helmchen, G. Enantioselective total synthesis of (–)- α -kainic acid. *Org. Lett.* **2010**, *12*, 1108–1111. [[CrossRef](#)] [[PubMed](#)]
48. Wardrop, D.J.; Burge, M.S. Total synthesis of (–)-dysibetaine via a nitrenium ion cyclization–dienone cleavage strategy. *Chem. Commun.* **2004**, 1230–1231. [[CrossRef](#)] [[PubMed](#)]
49. Remuzon, P. Trans-4-hydroxy-L-proline, a useful and versatile chiral starting block. *Tetrahedron* **1996**, *52*, 13803–13835. [[CrossRef](#)]
50. Obst, U.; Betschmann, P.; Lerner, C.; Seiler, P.; Diederich, F.; Gramlich, V.; Weber, L.; Banner, D.W.; Schönholzer, P. Synthesis of novel nonpeptidic thrombin inhibitors. *Helv. Chim. Acta* **2000**, *83*, 855–909. [[CrossRef](#)]
51. Zhou, Z.; Zheng, X.; Liu, J.; Li, J.; Wen, P.; Wang, H. L-tret-leucine-derived AmidPhos-Silver(I) chiral complexes for the asymmetric [3+2] cycloaddition of azomethine ylides. *Synlett* **2017**, *28*, 999–1003. [[CrossRef](#)]
52. Cayuelas, A.; Larrañaga, O.; Nájera, C.; Sansano, J.M.; de Cózar, A.; Cossío, F.P. Taniaphos AgF-catalyzed enantioselective 1,3-dipolar cycloaddition of stabilized ylides derived from 2,2-dimethoxyacetaldehyde. *Tetrahedron* **2016**, *72*, 6043–6051. [[CrossRef](#)]
53. Shi, J.-W.; Zhao, M.-X.; Lei, Z.-Y.; Shi, M. Axially chiral BINIM and Ni(II)-catalyzed highly enantioselective 1,3-dipolar cycloaddition reactions of azomethine ylides and N-arylmaleimides. *J. Org. Chem.* **2008**, *73*, 305–308. [[CrossRef](#)] [[PubMed](#)]
54. Yavuz, S.; Özkan, H.; Tok, G.; Dişli, A. Facile method for 1,3-dipolar cycloaddition reaction of azomethine ylides: Highly stereoselective synthesis of substituted pyrrolidine derivatives. *J. Heterocycl. Chem.* **2013**, *50*, 1437–1440. [[CrossRef](#)]
55. Träff, A.; Lihammar, R.; Bäckvall, J.-E. Chemoenzymatic dynamic kinetic resolution approach to enantiomerically pure (R)- and (S)-duloxetine. *J. Org. Chem.* **2011**, *76*, 3917–3921. [[CrossRef](#)] [[PubMed](#)]
56. Zhou, J.-N.; Fang, Q.; Hu, Y.-H.; Yang, L.-Y.; Wu, F.-F.; Xie, L.-J.; Wu, J.; Li, S. Copper(II)-catalyzed enantioselective hydrosilylation of halo-substituted alkyl aryl and heteroaryl ketones: Asymmetric synthesis of (R)-fluoxetine and (S)-duloxetine. *Org. Biomol. Chem.* **2014**, *12*, 1009–1017. [[CrossRef](#)] [[PubMed](#)]

57. Hu, Q.; Zhang, Z.; Liu, Y.; Imamoto, T.; Zhang, W. ZnCl₂-Promoted asymmetric hydrogenation of β -secondary-amino ketones catalyzed by a *P*-chiral Rh-Bisphosphine complex. *Angew. Chem. Int. Ed.* **2015**, *54*, 2260–2264. [[CrossRef](#)] [[PubMed](#)]
58. Zirakzadeh, A.; Schuecker, R.; Gorgas, N.; Mereiter, K.; Spindler, F.; Weissensteiner, W. Ruthenium complexes of phosphino-substituted ferrocenyloxazolines in the asymmetric hydrogenation and transfer hydrogenation of ketones: A comparison. *Organometallics* **2012**, *31*, 4241–4250. [[CrossRef](#)]
59. Roux, E.L.; Malacea, R.; Manoury, E.; Poli, R.; Gonsalvi, L.; Peruzzini, M. Highly efficient asymmetric hydrogenation of alkyl aryl ketones catalyzed by iridium complexes with chiral planar ferrocenyl phosphino-thioether ligands. *Adv. Synth. Catal.* **2007**, *349*, 309–313. [[CrossRef](#)]
60. Zhang, A.-L.; Yu, Z.-D.; Yang, L.-W.; Yang, N.-F. Synthesis of several polyethers derived from BINOL and their application in the asymmetric borane reduction of prochiral ketones. *Tetrahedron Asymmetry* **2015**, *26*, 173–179. [[CrossRef](#)]
61. Yang, H.; Huo, N.; Yang, P.; Pei, H.; Lv, H.; Zhang, X. Rhodium catalyzed asymmetric hydrogenation of 2-pyridine ketones. *Org. Lett.* **2015**, *17*, 4144–4147. [[CrossRef](#)] [[PubMed](#)]

Sample Availability: Samples of the compounds are not available from the authors.



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).